| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 3 days ago) | |
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 3 days ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 3 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 7 months ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 7 months ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 months from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(8 months from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(2 years from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(2 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(2 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(5 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(5 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(5 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(5 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(5 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(5 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(6 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(6 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(6 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(6 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(6 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(6 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(7 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(7 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(7 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(7 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(7 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(8 years from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(8 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(10 years from now) | |
Abilify Mycite Kit is owned by Otsuka.
Abilify Mycite Kit contains Aripiprazole.
Abilify Mycite Kit has a total of 34 drug patents out of which 5 drug patents have expired.
Expired drug patents of Abilify Mycite Kit are:
- US9089567
- US7053092
- US8642760
- US9359302
- US8580796
Abilify Mycite Kit was authorised for market use on 13 November, 2017.
Abilify Mycite Kit is available in tablet;oral dosage forms.
Abilify Mycite Kit can be used as acute treatment of manic and mixed episodes associated with bipolar i disorder; adjunctive treatment of major depressive disorder (mdd); treatment of schizophrenia, method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient, method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver, method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver, adjunctive treatment of major depressive disorder (mdd), treatment of schizophrenia, method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient, acute treatment of manic and mixed episodes associated with bipolar i disorder.
The generics of Abilify Mycite Kit are possible to be released after 15 October, 2033.
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to ident...
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic